by The India large volume parenteral market size was estimated at around USD 95.44 million in 2022 and it is projected to hit around USD 160.72 million by 2032, growing at a CAGR of 5.35% from 2023 to 2032.
Key Pointers
- By Application, the nutritious injections segment held the largest revenue share of 46% in 2022.
- By Application, the therapeutic injections application segment is anticipated to grow at the fastest CAGR of 5.75% from 2023 to 2032.
- By End-use, the hospitals and other healthcare facilities segment generated the maximum market share of 96% in 2022.
- By End-use, the homecare facilities segment is expected to register significant growth between 2023 to 2032.
The Indian large volume parenteral (LVP) market has emerged as a significant player in the pharmaceutical landscape, reflecting a dynamic intersection of healthcare demands, technological advancements, and strategic investments. LVPs, commonly known as injectables, form a critical segment within the pharmaceutical industry, providing sterile solutions for intravenous administration.
Market Growth
The growth of the large volume parenteral (LVP) market in India is propelled by several key factors. Firstly, the escalating demand for LVPs stems from the increasing prevalence of chronic diseases and a burgeoning elderly population, driving the need for advanced therapeutic solutions. Secondly, significant technological advancements in pharmaceutical manufacturing have elevated production standards, ensuring the delivery of high-quality and sterile injectables. Government initiatives aimed at fortifying healthcare infrastructure and regulatory frameworks contribute to a conducive environment for market expansion. Moreover, the influx of strategic investments, both domestic and international, underscores the industry’s potential, leading to collaborations, mergers, and acquisitions to broaden product portfolios. While the market presents significant growth opportunities, challenges include navigating stringent regulatory compliance and maintaining stringent quality control measures, emphasizing the need for continuous investment in research, development, and manufacturing capabilities. Overall, these factors collectively shape the dynamic landscape of India’s LVP market, positioning it as a pivotal player in the global pharmaceutical sector.
Get a Sample: https://www.visionresearchreports.com/report/sample/41022
Report Scope of the India Large Volume Parenteral Market
| Report Coverage | Details |
| Growth rate from 2023 to 2032 | CAGR of 5.35% |
| Market Size in 2022 | USD 95.44 million |
| Revenue Forecast by 2032 | USD 160.72 million |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
Market Dynamics
Drivers
- Increasing Healthcare Needs: The surge in demand for large volume parenteral (LVP) products in India is primarily driven by the escalating healthcare needs of a population grappling with a rising incidence of chronic diseases. The imperative for effective therapeutic solutions has amplified the usage of sterile injectables in critical care scenarios and surgical interventions.
- Technological Advancements in Manufacturing: The Indian pharmaceutical sector has witnessed noteworthy advancements in manufacturing technologies, particularly in the production of LVPs. State-of-the-art facilities equipped with cutting-edge technology adhere to stringent quality standards, ensuring the development and delivery of high-quality sterile solutions.
Restraints
- Stringent Regulatory Compliance: One of the primary restraints facing the large volume parenteral (LVP) market in India is the challenge of adhering to stringent regulatory standards. The need to comply with rigorous international regulations poses a significant barrier, requiring substantial investments in research, development, and manufacturing processes to meet the necessary quality and safety benchmarks.
- Quality Control Imperatives: Maintaining stringent quality control measures is a critical restraint for the LVP market. Ensuring the sterility and quality of injectables is paramount, and any compromise in these aspects can have severe consequences. Industry stakeholders must continually invest in robust quality assurance mechanisms, adding to the operational complexity and costs.
Opportunities
- Rising Demand for Specialized Therapies: The increasing prevalence of complex medical conditions and the demand for specialized therapies provide an opportunity for the LVP market to diversify its product offerings. Tailoring injectables to address specific therapeutic areas and patient needs can unlock new avenues for growth and market penetration.
- Evolving Digital Health Ecosystem: The integration of digital health solutions presents opportunities for the LVP market, including smart packaging, real-time monitoring, and data-driven insights. Embracing digital technologies can enhance supply chain efficiency, product traceability, and overall customer experience.
Application Insights
The nutritious injections segment dominated the market with the largest revenue share of 46% in 2022. Its growth is attributed to increased demand for these formulations to fulfill adequate nutrition requirements and improve drug absorption for faster and more effective results. Different combinations of nutrients are available at different concentrations for different requirements. Parenteral nutrition is selected when a patient experiences short bowel syndrome, extensive Crohn’s disease, high-output gastrointestinal fistula, intractable vomiting, radiation enteritis, and mucositis after chemotherapy. Nutritious injections also reduce risks associated with the treatment of chronic diseases and ensure smoother therapy.
The therapeutic injections application segment is anticipated to grow at the fastest CAGR of 5.75% over the forecast period owing to the increasing prevalence of life-threatening diseases and growing demand for safer, faster, and more effective methods of drug administration in patients undergoing surgical procedures. The COVID-19 pandemic and the surging demand for these formulations owing to the rising patient population suffering from low immunity levels and prone to the incidence of neurological diseases, cardiac problems, cancers, and spinal injuries, to meet adequate nutritional requirements when enteral nutrition mode is insufficient, not possible, or contraindicated, has positively impacted the company sales and overall market growth.
Volume Insights
The 500 ml segment had a significant share in India large volume parenteral market in 2022. Growing awareness among healthcare professionals about hospital-associated malnutrition, rising number of surgeries, increasing preference for single-dose administration of vaccines and drugs, growing need for a faster route of drug administration to avoid complications, and an increase in local manufacturing are factors expected to drive the demand for LVP, which, in turn, can boost this segment. Moreover, rising demand for LVP formulations among critically ill patients, an increasing number of ICU admissions, and growing prevalence of various chronic disorders such as cancer and diabetes, are additional factors expected to propel market growth.
The 100 ml injectable segment is anticipated to register a significant growth rate during the forecast period. The increasing prevalence of chronic diseases and growing demand for LVP formulations for fulfilling adequate nutrition requirements, correcting electrolyte and fluid balance disturbances, and as a vehicle for administration of other drugs are key factors expected to drive this segment. For instance, patients weighing more than 50 kg and with no additional risk factors for hepatotoxicity, paracetamol infusion in 100 mL quantity is suggested for treating fever or pain, especially in post-surgery, when other means of administering medicine are not feasible or when the IV method is clinically suggested to urgently treat hyperthermia or pain. This, in turn, is anticipated to positively impact the growth of the segment.
End-use Insights
The hospitals and other healthcare facilities segment led the market with the largest revenue share of over 96% in 2022 and it is expected to grow at the fastest CAGR of 5.3% over the forecast period. The growth can be attributed to the increase in demand for these formulations among patients during surgery or while recovering in the hospital, as well as growing physician preferences for single-dose administration. In India, the prevalence of malnutrition has increased over the past few years. According to the 2018 State of Food Security and Nutrition in the World report, 195.9 million people are undernourished in India. Total Parenteral Nutrition (TPN) is an essential preparation for malnutrition, used in hospitalized patients where enteral feeding is not feasible or for critical care patients with compromised gastrointestinal tract function.
The homecare facilities segment is expected to register significant growth during the forecast period owing to the growing geriatric population and increasing consumer interests in the adoption of at-home care. According to a report, Elderly in India 2021, published by the National Statistical Office (NSO), the elderly population of India aged 60 years or above is estimated to increase by 56 million and reach 194 million by the year 2031 from 138 million in the year 2021. Similarly, according to an article published by Economic Times in April 2019, the share of the older population-those aged 60 years or above-in India is projected to increase to around 20% in 2050. This has resulted in an increased number of home care services that can manage dose administration in the geriatric population. Moreover, benefits offered by formulations such as high bioavailability and delivery of safer and faster drug absorption, are likely to boost segment growth.
Key Companies
- B. Braun SE
- Fresenius Kabi AG
- Baxter
- Otsuka Pharmaceutical Co., Ltd.
- Sichuan Kelun
- Albert David Ltd.
- BML Parenteral Drugs
India Large Volume Parenteral Market Report Segmentations:
By Application
- Therapeutic Injections
- Fluid Balance Injections
- Nutritious Injections
By Volume
- 100 ml
- 250 ml
- 500 ml
- 1,000 ml
- 2,000 ml
By End-use
- Hospitals and Other Healthcare Facilities
- Home Care
Buy this Premium Research Report@ https://www.visionresearchreports.com/report/checkout/41022
You can place an order or ask any questions, please feel free to contact sales@visionresearchreports.com| +1 650-460-3308
